Crestline Management LP Buys Shares of 24,744 Immunome, Inc. (NASDAQ:IMNM)

Crestline Management LP bought a new stake in Immunome, Inc. (NASDAQ:IMNM) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 24,744 shares of the company’s stock, valued at approximately $263,000.

Several other large investors also recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its stake in shares of Immunome by 2,540.4% during the fourth quarter. JPMorgan Chase & Co. now owns 648,610 shares of the company’s stock valued at $6,888,000 after acquiring an additional 624,045 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Immunome by 2,696.5% during the fourth quarter. Renaissance Technologies LLC now owns 316,000 shares of the company’s stock valued at $3,356,000 after acquiring an additional 304,700 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in shares of Immunome by 127.3% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 500,000 shares of the company’s stock valued at $5,310,000 after acquiring an additional 280,000 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Immunome by 12.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,282,754 shares of the company’s stock valued at $24,243,000 after acquiring an additional 246,447 shares during the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Immunome during the fourth quarter valued at $902,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on IMNM. Wedbush reiterated an “outperform” rating and set a $33.00 target price on shares of Immunome in a research report on Thursday, March 20th. Guggenheim reduced their target price on Immunome from $35.00 to $25.00 and set a “buy” rating on the stock in a research report on Thursday, March 20th. Lifesci Capital began coverage on Immunome in a research report on Tuesday, March 11th. They set an “outperform” rating and a $20.00 target price on the stock. Stephens reiterated an “overweight” rating and set a $30.00 target price on shares of Immunome in a research report on Thursday, March 20th. Finally, Lake Street Capital began coverage on Immunome in a research report on Wednesday, April 2nd. They set a “buy” rating and a $23.00 target price on the stock. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Immunome currently has an average rating of “Buy” and an average target price of $25.33.

Immunome Price Performance

Immunome stock opened at $7.46 on Monday. The stock’s 50-day moving average is $7.76 and its 200-day moving average is $9.94. The company has a market cap of $649.11 million, a price-to-earnings ratio of -0.92 and a beta of 2.00. Immunome, Inc. has a 12 month low of $5.15 and a 12 month high of $16.81.

Immunome (NASDAQ:IMNM) last released its quarterly earnings data on Wednesday, March 19th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). The firm had revenue of $2.74 million during the quarter, compared to analysts’ expectations of $3.07 million. Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. Research analysts anticipate that Immunome, Inc. will post -2.21 EPS for the current year.

Insider Transactions at Immunome

In related news, Director Jean Jacques Bienaime bought 7,000 shares of the company’s stock in a transaction that occurred on Monday, March 24th. The shares were acquired at an average cost of $8.21 per share, for a total transaction of $57,470.00. Following the acquisition, the director now owns 23,615 shares in the company, valued at $193,879.15. This represents a 42.13% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Clay B. Siegall bought 137,100 shares of the company’s stock in a transaction that occurred on Wednesday, March 26th. The shares were bought at an average price of $7.29 per share, for a total transaction of $999,459.00. Following the completion of the acquisition, the chief executive officer now owns 806,736 shares in the company, valued at approximately $5,881,105.44. This trade represents a 20.47% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 156,400 shares of company stock worth $1,160,495 in the last three months. 8.60% of the stock is currently owned by company insiders.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.